A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children’s oncology group
- 120 Downloads
The role of chemotherapy in the treatment of high-grade gliomas in children is unclear. Early reports were suggestive of improved outcome in children with high-grade glioma with the addition of chemotherapy after surgery and radiation therapy. Subsequent studies did not show similar favorable contribution of chemotherapy to the outcome of these children. Further efforts to identify active chemotherapy agents in children include use of agents that have shown efficacy in adult patients with high-grade glioma and agents that have shown promise in mice bearing human xenografts of brain tumors. A Pediatric Oncology Group (POG 9431) trial tested the activity of two such agents, procarbazine and topotecan in newly diagnosed patients with high-grade glioma who had measurable disease after diagnostic surgery. Neither agent showed efficacy within the confines of the statistical design of the study. This study showed that children with high-grade glioma have an innate resistance to alkylating agents based on mismatch repair deficiency and high levels of alkyguanine transferase (AGT). Future trials should consider strategies to overcome the resistance mechanisms in children with high-grade glioma.
KeywordsAGT activity in high-grade glioma in children high-grade glioma in children mismatch repair proteins in high-grade glioma in children phase II window therapy in high-grade glioma in children procarbazine in high-grade glioma in children resistance mechanisms in high-grade glioma in children topotecan in high-grade glioma in children
Unable to display preview. Download preview PDF.
- 1.Cohen ME, Duffner PK, Tebbi CK: Brain tumors in children: Diagnosis and management. In: Cameron K. Tebbi (ed) Major Topics in Pediatric and Adolescent Oncology. G.K. Hall and Co., Boston, 1982Google Scholar
- 6.Green SB, Byar DP, Walker MD, et al Comparisons of carmustine, procarbazine, and high-dose methylprednisone as additions to surgery and radiotherapy for the treatment of malignant glioma Cancer Treat Rpts 67(2): 121–132, 1983Google Scholar
- 8.Kumar ARV, Renaudin J, Wilson CB, et al Procarbazine hydrochloride in the treatment of brain tumors Neurosurgery 40:365–371, 1974Google Scholar
- 11.Friedman HS, Houghton PJ, Schold SC, et al Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts Can Chem Phar 32(2):171–174, 1994Google Scholar
- 12.Blaney SM, Balis FM, Cole DE, et al Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion Can Res 53:1032–1036, 1993Google Scholar
- 16.Friedman HS, McLendon RE, Kerby T et al.: DNA mismatch repair and O-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 16(12): 3851–3857Google Scholar
- 19.D’Argenio DZ, Schumitzky A: ADAPT II User’s Guide, 1st edn. Biomedical Simulations Resource, USC, Los Angeles, 1990Google Scholar
- 20.Gibaldi M, Perrier D: Pharmacokinetics, 2nd edn. New York, 1982Google Scholar
- 28.Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold Jr SC, Phase I trial of O6-Benzylguanine for patients undergoing surgery for malignant glioma J Clin Oncol 16:3570–3575, 1998PubMedGoogle Scholar